Suppr超能文献

秘鲁结直肠肿瘤的重要临床分子特征:错配修复缺陷高发和 KRAS 突变低发。

Clinically important molecular features of Peruvian colorectal tumours: high prevalence of DNA mismatch repair deficiency and low incidence of KRAS mutations.

机构信息

Oncología Molecular, Hospital Universitario Elche, Spain.

出版信息

Pathology. 2011 Apr;43(3):228-33. doi: 10.1097/PAT.0b013e3283437613.

Abstract

BACKGROUND

The incidence of colorectal cancer (CRC) in Peru has been increasing, and no data have been published on the molecular features. We explored the most relevant genetic events involved in colorectal carcinogenesis, with clinical implications.

METHODS

Using immunohistochemistry for mismatch-repair (MMR) proteins (MLH1, MSH2, MSH6, and PMS2) and microsatellite instability analysis, we evaluated the status of 90 non-selected CRC Peruvian patients followed in a nationwide reference hospital for cancer (INEN, Lima). Tumours with loss of hMLH1 were evaluated further for hMLH1 promoter hypermethylation and all cases were evaluated for the presence of KRAS and BRAF-V600E mutations.

RESULTS

MMR deficiency was found in 35 (38.8%) patients. We identified an unexpected association between MMR deficiency and older age. Among the 14 cases with loss of MLH1, 10 samples exhibited hypermethylation. Of the 90 cases evaluated, 15 (16.7%) carried KRAS mutations; we found one previously unreported mutation (G13R).

CONCLUSIONS

Peruvian CRC tumours exhibited the highest prevalence of MMR deficiency reported to date. The expected hereditary component was also high. The age of onset of these MMR deficient tumours was greater than that observed for non-MMR deficient cases, suggesting the ineffectiveness of the Bethesda criteria for Lynch syndrome screening in Peru. Prospective studies are warranted to define the molecular characteristics of CRC in this population.

摘要

背景

秘鲁的结直肠癌(CRC)发病率一直在上升,但尚未发表有关其分子特征的资料。我们探讨了与结直肠癌变相关的最相关的遗传事件,并探讨了其临床意义。

方法

我们使用免疫组织化学方法检测错配修复(MMR)蛋白(MLH1、MSH2、MSH6 和 PMS2)和微卫星不稳定性分析,评估了在全国癌症参考医院(利马的 INEN)接受治疗的 90 例非选择性秘鲁 CRC 患者的肿瘤状态。对 hMLH1 缺失的肿瘤进一步进行 hMLH1 启动子甲基化评估,所有病例均评估 KRAS 和 BRAF-V600E 突变情况。

结果

35 例(38.8%)患者存在 MMR 缺陷。我们发现 MMR 缺陷与年龄较大之间存在意外关联。在 14 例 MLH1 缺失的病例中,有 10 例样本存在甲基化。在评估的 90 例病例中,有 15 例(16.7%)携带 KRAS 突变;我们发现了一种以前未报道过的突变(G13R)。

结论

秘鲁 CRC 肿瘤表现出迄今为止报道的最高 MMR 缺陷发生率。预期的遗传性成分也很高。这些 MMR 缺陷型肿瘤的发病年龄大于非 MMR 缺陷型病例,这表明贝塞斯达标准不适用于秘鲁林奇综合征筛查。需要进行前瞻性研究以确定该人群 CRC 的分子特征。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验